Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

ACADIA Pharmaceuticals

NASDAQ ACAD
$15.12 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 25 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

2.52B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
2.34B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.66
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
166.62M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-51.71 %

Upcoming events ACADIA Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart ACADIA Pharmaceuticals

Stock analysis ACADIA Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1,473.30 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
5.84 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
385.58 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-29.54 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-0.37 7.67

Price change ACADIA Pharmaceuticals per year

15.68$ 57.46$
Min Max

Summary analysis ACADIA Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure ACADIA Pharmaceuticals

Revenue and net income ACADIA Pharmaceuticals

All parameters

Stock news ACADIA Pharmaceuticals

All news
22 November 2023 в 01:24

Acadia Pharmaceuticals' Research and Development Head to Exit

22 November 2023 в 01:24

Acadia Pharmaceuticals' Research and Development Head to Exit

13 July 2023 в 23:45

Acadia Pharmaceuticals stock rockets 30% following expanded drug rights

12 September 2022 в 14:55

Acadia Pharmaceuticals: FDA Accepts New Drug Application for Trofinetide

12 September 2022 в 14:55

Acadia Pharmaceuticals: FDA Accepts New Drug Application for Trofinetide

21 June 2022 в 15:06

Acadia Pharmaceuticals Shares Tumble Premarket After FDA Panel Vote >ACAD

21 June 2022 в 15:06

Acadia Pharmaceuticals Shares Tumble Premarket After FDA Panel Vote >ACAD

17 June 2022 в 14:20

Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis

9 March 2022 в 19:12

Acadia Pharmaceuticals Shares Rise 16% After New Target Action Date for Pimavanserin NDA

9 March 2022 в 19:12

Acadia Pharmaceuticals Shares Rise 16% After New Target Action Date for Pimavanserin NDA

9 March 2022 в 16:51

Acadia Pharmaceuticals Gets Target Action Date for sNDA for Pimavanserin

9 March 2022 в 16:51

Acadia Pharmaceuticals Gets Target Action Date for sNDA for Pimavanserin

6 January 2022 в 16:10

Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month?

21 December 2021 в 00:40

Acadia Pharmaceuticals Rise 16% on Resubmission Plan for Pimavanserin

21 December 2021 в 00:40

Acadia Pharmaceuticals Rise 16% on Resubmission Plan for Pimavanserin

7 April 2021 в 19:15

Почему акции Acadia Pharmaceuticals потеряли почти 60%

About company ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Address:
12830 El Camino Real, San Diego, CA, United States, 92130
Company name: ACADIA Pharmaceuticals
Issuer ticker: ACAD
ISIN: US0042251084
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2004-05-27
Sector: Healthcare
Industry: Biotechnology
Site: https://www.acadia-pharm.com

On which stock exchange are ACADIA Pharmaceuticals (ACAD) stocks traded?

ACADIA Pharmaceuticals (ACAD) stocks are traded on NASDAQ.

What is the ticker of ACADIA Pharmaceuticals stocks (ACAD)?

The stock ticker of ACADIA Pharmaceuticals’s stocks or in other words, the code is ACAD. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does ACADIA Pharmaceuticals (ACAD) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, ACADIA Pharmaceuticals (ACAD) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are ACADIA Pharmaceuticals (ACAD) stocks traded?

ACADIA Pharmaceuticals (ACAD) stocks are traded on the NASDAQ exchange in dollars.

What is the price of ACADIA Pharmaceuticals (ACAD) stocks today?

The current price of ACADIA Pharmaceuticals stocks on 17.05.2024 is 15.12 dollars. per share.

What is the dynamics of ACADIA Pharmaceuticals (ACAD) stocks from the beginning of the year?

ACADIA Pharmaceuticals (ACAD) quotes have increased by -51% from the beginning of the year up to 15.12 dollars. per 1 stocks.

How much did ACADIA Pharmaceuticals (ACAD) stocks increase in мае 2024?

This month ACADIA Pharmaceuticals (ACAD) quotes have increased by -11.32% to 15.12 dollars. per share.

How much are ACADIA Pharmaceuticals (ACAD) stocks worth?

Today, on October, 17.05.2024 ACADIA Pharmaceuticals’s (ACAD) stocks cost 15.12 dollars..

What is the market capitalization of ACADIA Pharmaceuticals (ACAD)?

Capitalization is the market value of ACADIA Pharmaceuticals (ACAD) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 17.05.2024, the market capitalization of ACADIA Pharmaceuticals (ACAD) is estimated at about 2519339760 dollars.